X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
SM-030 (ruboxistaurin) is a first-in-class selective and potent topical gel which is designed to inhibit PKCβ, which is the key and final enzyme in the melanin synthesis pathway, thus reduces the production of excess epidermal melanin.
Lead Product(s): Ruboxistaurin
Therapeutic Area: Dermatology Product Name: SM-030
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2023
Details:
Acquisition of clinical-stage biotechnology company Chromaderm by DermBiont, will accelerate the development of Chromaderm’s drug candidate, ruboxistaurin (SM-030), topical formulation of the first and only targeted drug to treat skin hyperpigmentation.
Lead Product(s): Ruboxistaurin
Therapeutic Area: Dermatology Product Name: SM-030
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: DermBiont
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 21, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
